Application of uliestat acetate for clinical impact first imitation

According to the website of the State Food and Drug Administration (CFDA) on April 11, the 3.1 contraceptive new drug of HISCO, uliestat acetate and uliestat acetate tablets, applied for clinical application and ranked among the first to be imitated Ulinastatin acetate is a selective progesterone receptor modulator developed by labora toire HRA Pharma Company in France It belongs to short acting oral contraceptive The drug was approved by FDA in August 2010, Its trade name is Ella, which is sold by Watson company It is the only prescription product that is taken orally within 120 hours (5 days) after contraceptive failure or unprotected sexual life to avoid pregnancy Compared with the most commonly used emergency contraceptive levonorgestrel, ulinastate acetate has the potential benefit of preventing more unwanted pregnancies and has wider clinical applicability At present, although there are no manufacturers in China, there are many enterprises that have impacted on the first generic drugs More than 10 pharmaceutical enterprises have applied for clinical application, and hisilico has now joined the ranks of competition However, the R & D and production capacity of competitors should not be underestimated, such as Hengrui pharmaceutical, Shaanxi step pharmaceutical, etc Hispec is the leader in the field of parenteral nutrition medicine, characteristic anti infective medicine and hepatobiliary disease medicine in China At present, it also extends antennae to anti allergy, corticosteroids and other fields In the prospectus, the company has said that it will focus on tracking the development trend of innovative generic drugs in the international mainstream market, and establish the domestic leading new drug variety reserve resources.